Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
Clinical trial NCT04595565 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04595565
- Sponsor
- GBG Forschungs GmbH
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-28
- Primary completion
- 2027-03-30
- Enrollment
- 1332
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.